Dendreon (DNDN) Surges After Sales, Commercialization Update
Tweet
Share
E-mailGet Alerts DNDN Hot Sheet
Price: $0.13 --0%
Financial Fact:
Research and development: 9.38M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Research and development: 9.38M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Shares of Dendreon (Nasdaq: DNDN) are surging in early action Thursday after providing fourth quarter gross PROVENGE guidance of approximately $82 million.
There are varying consensus estimates on the gross sales, but some are saying it was a "beat." Bloomberg said the consensus is $72.2 million, but claims this "may not compare."
The company also sees modest quarter-over-quarter growth in 2012.
Gross PROVENGE revenue for the year was approximately $228 million.
The company also announced a number of other updates, inccluding the fact that the CMS updated their coverage policy to now cover the infusion costs associated with the administration of PROVENGE (this was originally announced in Nov.)
Share are up 25 percent in early action.
There are varying consensus estimates on the gross sales, but some are saying it was a "beat." Bloomberg said the consensus is $72.2 million, but claims this "may not compare."
The company also sees modest quarter-over-quarter growth in 2012.
Gross PROVENGE revenue for the year was approximately $228 million.
The company also announced a number of other updates, inccluding the fact that the CMS updated their coverage policy to now cover the infusion costs associated with the administration of PROVENGE (this was originally announced in Nov.)
Share are up 25 percent in early action.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anthropic hires Google chip veteran as it pushed into hardware - Bloomberg
- Citadel has shed over 80% of aggregate risk from Situational Awareness portfolio - CNBC
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
Create E-mail Alert Related Categories
Guidance, Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
